After the tax investigation, what are the new actions of relevant pharmaceutical enterprises?

[pharmaceutical Station industry trends] after the Ministry of Finance set up an open exhibition on the quality inspection of accounting information in the pharmaceutical industry in 2019, there was a heated discussion in the pharmaceutical industry Now, the heat of this event is slowly decreasing At present, what are the new actions of 77 pharmaceutical companies? What are the impacts? Start to cancel subsidiaries "The past era of barbaric growth has passed The general direction of the state for the pharmaceutical industry is comprehensive compliance The contents and schedule of this inspection are fully disclosed, which specifically tells the enterprise how to do it It is more like the compliance operation guide issued by the relevant national departments Through policy measures, the enterprise can know how to achieve compliance Battalion " Within the time after the notice was issued, some media said that some pharmaceutical companies disclosed that their companies had started to sell their subsidiaries The industry reminds that in the storm of tax investigation, those pharmaceutical enterprises with high sales costs, as well as those with non-compliance such as affiliated operation, money laundering through tickets and sales with money, should be prepared Investors believe that the high cost of sales is a common feature of the pharmaceutical industry, some companies may not be able to withstand the test, so the market looks at the action of the Ministry of finance as a negative It is reported that at the end of the day, the Shenwan pharmaceutical bio index fell 1.56%, combined with the total market value of the bio pharmaceutical industry, the market value of this plate fell by more than 50 billion yuan in the same day Specifically, as one of the key inspection enterprises, Zhongheng group's sales expenses reached 2.119 billion yuan, a year-on-year increase of 198.45%, accounting for 64.23% of the revenue in the same period, and the average daily sales expenses reached 5.8 million yuan It is understood that on June 20, the stock price of Zhongheng group has dropped below 2.9 yuan At present, the company's P / E ratio hovers around 14, and the market valuation is in a historical position The P / E ratio is close to the recent Shanghai Composite Index by 13 times, which is lower than the world's major stock indexes In addition, Zhongheng group has no trend to buy back shares at present In addition to the actions and influences of canceling subsidiaries and falling stock prices, some pharmaceutical enterprises have also changed their positions The author understands that Guangxi Wuzhou Pharmaceutical Co., Ltd of Zhongheng group has successively announced that Ouyang Jingbo, general manager and vice chairman of the company, and Liao Zhi, deputy general manager, have resigned In addition, Bai Lixi, director and director general of Taiji group, resigned and announced that he would no longer be the legal representative of the company, while Li Yangchun became the next Taiji group According to the industry analysis, Taiji Group's key work in 2019, more emphasis on sales planning, and the style of new executives may also affect the focus of the enterprise's work However, there are also pharmaceutical companies that say the inspection has no significant impact The person in charge of a pharmaceutical enterprise selected for inspection said frankly that he had not encountered such a large-scale thorough inspection of the quality of accounting information of pharmaceutical enterprises for many years before However, he said that the audit process of the company was completed by a professional third party every year, and the inspection would not have a great impact on the enterprise.